Hybio Pharmaceutical (SHE:300199) submitted its marketing authorization application to China's National Medical Products Administration for its tirzepatide injection, according to a Saturday filing with the Shenzhen bourse.
The drug is indicated for type 2 diabetes, weight management, and sleep apnea, the company said in its filing.
Shares closed 4% higher on Monday.